In this study, the hypothesis that the addition of ibrutinib and lenalidomide would inhibit BCR signaling and NF-κB in ABC DLBCL and thereby enhance sensitivity to DA-EPOCH-R was assessed. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.